Therorna funding to accelerate circRNA-based platform
Therorna Inc., a Chinese biotech company specializing in the development of circular RNA (circRNA) technology-based…
Therorna Inc., a Chinese biotech company specializing in the development of circular RNA (circRNA) technology-based…
New Zealand biotech company Amaroq Therapeutics said it is progressing towards clinical trials following a…
Attempts to increase global Covid-19 vaccine coverage with a temporary patent waiver have been met…
The first RNA interference therapy was approved in 2018, after 20 years in development. What…
Cardiovascular diseases may not regularly grab the headlines, but they’re the leading cause of mortality…
The Covid-19 pandemic caused huge disruption for European biotech in 2020, but the industry pulled…
A once forgotten technology, RNA editing has been gaining traction as a treatment for genetic…
AstraZeneca is recruiting RNAi specialist Silence Therapeutics to develop treatments for cardiovascular, renal, metabolic, and…
US biotech Alnylam Pharmaceuticals has succeeded in getting its second RNAi drug -- for treatment…
RNA vaccine developer CureVac will receive a grant of up to €8.3M from a global…
The UK biotech MiNA Therapeutics has launched a collaboration with AstraZeneca to develop small activating…
A CAR T-cell therapy amplified by RNA technology, developed by BioNTech, has shown preclinical potential…